David B. Van Wyck

1.9k total citations
43 papers, 1.4k citations indexed

About

David B. Van Wyck is a scholar working on Hematology, Genetics and Nephrology. According to data from OpenAlex, David B. Van Wyck has authored 43 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 15 papers in Genetics and 9 papers in Nephrology. Recurrent topics in David B. Van Wyck's work include Erythropoietin and Anemia Treatment (19 papers), Iron Metabolism and Disorders (17 papers) and Hemoglobinopathies and Related Disorders (15 papers). David B. Van Wyck is often cited by papers focused on Erythropoietin and Anemia Treatment (19 papers), Iron Metabolism and Disorders (17 papers) and Hemoglobinopathies and Related Disorders (15 papers). David B. Van Wyck collaborates with scholars based in United States, Australia and United Kingdom. David B. Van Wyck's co-authors include Antoinette Mangione, Charles L. Witte, Mark G. Martens, Melvin H. Seid, Stephen E. McMurray, Marlys H. Witte, Suzanne Gagnon, Nathan W. Levin, Chaim Charytan and John C. Morrison and has published in prestigious journals such as PLoS ONE, Annals of the New York Academy of Sciences and Kidney International.

In The Last Decade

David B. Van Wyck

41 papers receiving 1.4k citations

Peers

Countries citing papers authored by David B. Van Wyck

Since Specialization

Citations

This map shows the geographic impact of David B. Van Wyck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David B. Van Wyck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David B. Van Wyck more than expected).

Fields of papers citing papers by David B. Van Wyck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David B. Van Wyck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David B. Van Wyck. The network helps show where David B. Van Wyck may publish in the future.

Co-authorship network of co-authors of David B. Van Wyck

This figure shows the co-authorship network connecting the top 25 collaborators of David B. Van Wyck. A scholar is included among the top collaborators of David B. Van Wyck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David B. Van Wyck. David B. Van Wyck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Urgent-Start Peritoneal Dialysis and Outcomes 2020 ·Journal of the American Society of Nephrology ·(unknown), Scott Sibbel, Dena E. Cohen, (unknown), David B. Van Wyck, Arshia Ghaffari, Martin J. Schreiber, Francesca Tentori, Steven M. Brunelli	1
2	Impact of Rescheduling a Missed Hemodialysis Treatment on Clinical Outcomes 2019 ·Kidney Medicine ·Dena E. Cohen, (unknown), (unknown), David B. Van Wyck, Francesca Tentori, Steven M. Brunelli	4
3	Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial 2016 ·PLoS ONE ·Sandrine Gaillard, Andreas Böck, Fernando Carrera, Kai‐Uwe Eckardt, David B. Van Wyck, Sukhvinder S. Bansal, Maureen Cronin, (unknown), Sylvain Larroque, Simon D. Roger, Iain C. Macdougall	28
4	Knowing What We Do and Doing What We Should: Quality Assurance in Hemodialysis 2014 ·Nephron Clinical Practice ·(unknown), Juan P. Bosch, Cláudia Barth, Christian Combe, John T. Daugirdas, Jörgen Hegbrant, Georges Martín, Christopher W. McIntyre, Dónal O’Donoghue, Hector J. Rodriguez, Antonio Santoro, James Tattersall, (unknown), David B. Van Wyck, Bernard Canaud	8
5	Within‐patient variation of hemoglobin and reticulocytes: implications for evaluating ESA responsiveness in dialysis patients 2012 ·International Journal of Laboratory Hematology ·David B. Van Wyck, I.P. Giles, Ken Sharpe	1
6	Analytical and Biological Variation in Measures of Anemia and Iron Status in Patients Treated With Maintenance Hemodialysis 2010 ·American Journal of Kidney Diseases ·David B. Van Wyck, Harry Alcorn, Resmi Gupta	22
7	Intravenous Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Postpartum Anemia 2007 ·Obstetrics and Gynecology ·David B. Van Wyck, Mark G. Martens, Melvin H. Seid, (unknown), Antoinette Mangione	179
8	Effect of Intravenous Iron Sucrose in Peritoneal Dialysis Patients Who Receive Erythropoiesis-Stimulating Agents for Anemia 2006 ·Clinical Journal of the American Society of Nephrology ·Harmeet Singh, John Reed, (unknown), José L. Cangiano, David B. Van Wyck	38
9	Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients 2005 ·Nephrology Dialysis Transplantation ·B. A. J. Walters, David B. Van Wyck	39
10	A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD 2005 ·Kidney International ·David B. Van Wyck, (unknown), (unknown), (unknown), Stephen E. McMurray	175
11	Making sense: a scientific approach to intravenous iron therapy. 2004 ·PubMed ·David B. Van Wyck, Bo G. Danielson, George R. Aronoff	9
12	Just the FAQs: Frequently asked questions about iron and anemia in patients with chronic kidney disease 2002 ·American Journal of Kidney Diseases ·David B. Van Wyck, George R. Bailie, George R. Aronoff	16
13	Efficacy and Safety of Iron Sucrose for Iron Deficiency in Patients With Dialysis-Associated Anemia: North American Clinical Trial 2001 ·American Journal of Kidney Diseases ·Chaim Charytan, Nathan W. Levin, (unknown), (unknown), Suzanne Gagnon, David B. Van Wyck	100
14	Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial 2000 ·American Journal of Kidney Diseases ·David B. Van Wyck, (unknown), (unknown), Rohini Adhikarla, Suzanne Gagnon, Chaim Charytan, Nathan W. Levin	106
15	Erythropoietin Level and Effect of rHuEPO in Beta‐Thalassemic Mice^a 1998 ·Annals of the New York Academy of Sciences ·Raymond A. Popp, S G Shinpock, (unknown), Gisela K. Clemons, David B. Van Wyck	1
16	Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: A prospective analysis and comparison of two agents 1996 ·American Journal of Kidney Diseases ·Denise J. Roe, Antonia Harford, Philip G. Zager, Thomas B. Wiltbank, (unknown), (unknown), David B. Van Wyck	21
17	Iron status in patients receiving erythropoietin for dialysis-associated anemia 1989 ·Kidney International ·David B. Van Wyck, John C. Stivelman, Joaquı́m Ruiz, (unknown), Murray A. Katz, David A. Ogden	171
18	Coccidioidal Peritonitis Associated With Continuous Ambulatory Peritoneal Dialysis 1988 ·American Journal of Kidney Diseases ·Neil M. Ampel, (unknown), (unknown), (unknown), David B. Van Wyck, John N. Galgiani	19
19	LeVeen Shunt Endocarditis 1984 ·Archives of Internal Medicine ·David B. Van Wyck	0
20	Ischaemia and partial resection for control of splenic hyperfunction 1982 ·British journal of surgery ·Charles L. Witte, David B. Van Wyck, Marlys H. Witte, James J. Corrigan, Charles F. Zukoski, Gregory R. Pond, J.M. Woolfenden	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact